English translation

SymBio Pharmaceuticals Limited

Summary of Financial Statements for the Fiscal Year Ended December 31, 2012
[Japanese GAAP] (Non-consolidated)

February 14, 2013

Company Name	SymBio Pharmaceuticals Limited	Listing: Osaka Securities Exchange	
Securities code	4582	URL http://www.symbiopharma.com/	
Representative	Representative Director, President and Chief Executive Officer	Fuminori Yoshida	
Contact person	Director, Chief Financial Officer	Hiroki Maekawa	TEL 03(5472) 1125
Ordinary Annual General Meeting of Shareholders	March 28, 2013	Date of dividend payment (plan)	—
Scheduled date to file Securities Report	March 29, 2013		
Supplementary materials for the financial statements	Yes [No]		
Holding of earnings performance review:	[Yes] No (For securities analysts and institutional investors)		

Millions of yen – rounded down, unless otherwise stated

1. Business Results for FY 2012 (January 1, 2012 to December 31, 2012)

(1) Operating results (Percentages indicate year-on-year changes.)

	Net sales		Operating income (loss)		Ordinary income (loss)		Net income (loss)	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
FY 2012	1,955	3.9	(1,700)	-	(1,729)	-	(1,733)	-
FY 2011	1,882	29.8	(2,066)	-	(2,095)	-	(2,104)	-

	Net income (loss) per share	Diluted net income per share	Ratio of net income (loss) to equity (ROE)	Ratio of ordinary income (loss) to total assets (ROA)	Ratio of operating income (loss) to net sales
	Yen	Yen	%	%	%
FY 2012	(90.60)	-	(30.2)	(27.1)	(87.0)
FY 2011	(143.60)	-	(39.4)	(36.4)	(109.8)

(Reference) Equity in earnings FY 2012 - Millions of yen FY 2011 - Millions of yen

(2) Financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
FY 2012	5,502	4,899	88.6	254.71
FY 2011	7,256	6,605	91.0	345.28

(Reference) Net assets excluding subscription rights to shares:
FY 2012 4,872 Millions of yen FY 2011 6,605 Millions of yen

(3) Cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of the year
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
FY 2012	(1,658)	(410)	(0)	4,240
FY 2011	(2,074)	(117)	4,610	6,310

2. Dividends

	Annual dividend per share					Total dividends	Payout ratio	Ratio of dividends to net assets
	1st quarter	2nd quarter	3rd quarter	Fiscal Year End	Full year			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
FY 2011	-	0.00	-	0.00	0.00	0	0.0	0.0
FY 2012	-	0.00	-	0.00	0.00	0	-	0.0
FY 2013 (Forecast)	-	0.00	-	0.00	0.00		-	

3. Earnings forecasts for FY 2013 (January 1, 2013 to December 31, 2013)

(Percentages indicate year-on-year changes.)

	Net sales		Operating income (loss)		Ordinary income (loss)		Net income (loss)		Net income (loss) per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full Year	1,927	(1.4)	(1,889)	-	(1,922)	-	(1,926)	-	(81.03)

Notes:

(1) Changes in Accounting Policies, changes in accounting estimates and restatements after error corrections

(a) Changes in accounting polices due to revision of accounting standards:	Yes	No
(b) Changes in accounting polices due to other reason:	Yes	No
(c) Changes in accounting estimates:	Yes	No
(d) Restatements after error corrections:	Yes	No

(2) Number of shares outstanding (Common stock)

(i) Number of shares outstanding at the end of the year (including treasury stock)	FY 2012	19,130,900shares	FY 2011	19,130,900shares
(ii) Number of shares of treasury stock at the end of the year	FY 2012	75shares	FY 2011	75 shares
(iii) Average number of shares during the year	FY 2012	19,130,825shares	FY 2011	14,655,716shares

(Note) Refer to “Per share information” on Page 49 for number of shares that forms the basis for calculating net income (loss) per share.

* The status of the annual audit

The audit of financial statements as required by the Financial Instruments and Exchange Act is proceeding as of the date of this disclosure document.

*Explanation regarding the appropriate uses of earnings forecasts and other matters

(Notes on the forward-looking statements)

All forecasts presented in this document including earnings forecasts are based on the information currently available to the management and the assumptions that we judge reasonable. Actual results may differ substantially from these forecasts due to various factors. Regarding the assumptions on which the earnings forecasts are based and its usage, please refer to “Business results analysis” on Page 1 of the attachment.